Everolimus Modulation of Anti-tumor T CD4 Immune Responses
NCT02837757 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2022-05-16
Summary
Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma.
The objective of this study is to investigated the influence of everolimus immune modulation on antitumor efficacy .
Conditions
- Metastatic Renal Cancer
Interventions
- OTHER
-
Biological samples
blood and tumor tissue samples
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Besancon
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-30
- Primary Completion
- 2019-12-18
- Completion
- 2019-12-18
Countries
- France
Study Locations
More Related Trials
-
This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas
NCT01279772 ·Status: TERMINATED
-
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
NCT03367819 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
NCT01198665 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
NCT00176501 ·Status: TERMINATED ·Phase: PHASE2
-
Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
NCT00773149 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma
NCT00007956 ·Status: COMPLETED ·Phase: PHASE1
-
Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma
NCT03399747 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
NCT00169156 ·Status: COMPLETED ·Phase: PHASE2
-
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
NCT03671590 ·Status: TERMINATED ·Phase: PHASE1
-
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
NCT01125293 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
NCT00976248 ·Status: COMPLETED ·Phase: PHASE2
-
Reduced Chemotherapy in Low Risk DLBCL
NCT02752815 ·Status: UNKNOWN ·Phase: PHASE4
-
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00014560 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
NCT03241173 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
NCT01871727 ·Status: COMPLETED ·Phase: PHASE3
-
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT00869999 ·Status: COMPLETED ·Phase: PHASE2
-
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
NCT01665768 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Large B-cell Lymphoma
NCT06988085 ·Status: NOT_YET_RECRUITING
-
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
NCT00790036 ·Status: COMPLETED ·Phase: PHASE3
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT06510361 ·Status: RECRUITING ·Phase: PHASE2
-
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
NCT01066689 ·Status: UNKNOWN ·Phase: PHASE3
-
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
NCT06238648 ·Status: RECRUITING ·Phase: PHASE2
-
A Combination Study of CAR-T Therapy in r/r B-NHL
NCT05871684 ·Status: UNKNOWN ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT04082936 ·Status: TERMINATED ·Phase: PHASE1/PHASE2